Drug
Ux007
Ux007: highest development phase Phase 3, developed by Ultragenyx Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| UX007 NCT02960217 | Phase 3 | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) |
| UX007 NCT01886378 | Phase 2 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) |
Latest
No recent events.
Follow Ux007 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.